Tiziana's intranasal MS drug shows lower dose cuts neuroinflammation, higher dose falls short in Phase 2a trial

Tiziana Life Sciences reported results from its mid‑stage Inform‑MS trial, a Phase 2a study that enrolled 48 patients with non‑active secondary progressive multiple sclerosis. Participants received intranasal foralumab at either 50 µg or 100 µg doses, or placebo, over a 12‑week period.

The lower 50 µg dose achieved a statistically significant reduction in white‑matter/global‑brain SUV ratio on PET scans, meeting one of the trial’s primary neuroinflammation endpoints. This suggests the lower dose can dampen neuroinflammatory activity in this patient population.

In contrast, the higher 100 µg dose did not demonstrate a significant change in the same imaging metric, missing the neuroinflammation goal. However, both dose groups, along with placebo, completed treatment without any serious adverse events linked to the drug.

Overall safety was comparable across arms, with treatment‑emergent adverse events reported in 76.7% of drug‑treated patients versus 83.3% of placebo recipients. The mixed efficacy signals highlight a dose‑dependent response that will inform further development of foralumab for progressive MS.